metoclopramide has been researched along with Body Weight in 33 studies
Metoclopramide: A dopamine D2 antagonist that is used as an antiemetic.
metoclopramide : A member of the class of benzamides resulting from the formal condensation of 4-amino-5-chloro-2-methoxybenzoic acid with the primary amino group of N,N-diethylethane-1,2-diamine.
Body Weight: The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.
| Excerpt | Relevance | Reference |
|---|---|---|
| " This difference was still significant when controlling for age, body weight, history of motion sickness, previous PONV episodes, duration of anesthesia, and intraoperative fentanyl consumption using a logistic model." | 9.08 | Ondansetron versus metoclopramide in the treatment of postoperative nausea and vomiting. ( Finco, G; Gottin, L; Grosso, S; Ischia, S; Mosaner, W; Pinaroli, AM; Polati, E; Verlato, G, 1997) |
| "The present study was designed to investigate the influence of body weight on the prolactin responsiveness to metoclopramide and thyrotrophin-releasing hormone (TRH) in secondary amenorrhoeic women." | 9.07 | Effects of body weight on responses of serum prolactin to metoclopramide and thyrotrophin-releasing hormone in secondary amenorrhoeic women. ( Aono, T; Higuchi, K; Morishita, H; Takemoto, M; Yoshida, J, 1994) |
| "The effect of metoclopramide on gastroesophageal reflux was studied in 30 infants less than 1 year of age." | 9.06 | Randomized, prospective double-blind trial of metoclopramide and placebo for gastroesophageal reflux in infants. ( Calhoun, J; Kauffman, RE; Kuhns, L; Tolia, V, 1989) |
| "Using an original high-pressure liquid chromatographic assay, we measured serum levels of metoclopramide and defined a concentration-response relationship for metoclopramide control of cisplatin-induced emesis." | 7.67 | Optimizing metoclopramide control of cisplatin-induced emesis. ( Drayer, DE; Lewin, M; Lonski, L; Meyer, BR; Pasmantier, M; Reidenberg, MM, 1984) |
| " This difference was still significant when controlling for age, body weight, history of motion sickness, previous PONV episodes, duration of anesthesia, and intraoperative fentanyl consumption using a logistic model." | 5.08 | Ondansetron versus metoclopramide in the treatment of postoperative nausea and vomiting. ( Finco, G; Gottin, L; Grosso, S; Ischia, S; Mosaner, W; Pinaroli, AM; Polati, E; Verlato, G, 1997) |
| "The present study was designed to investigate the influence of body weight on the prolactin responsiveness to metoclopramide and thyrotrophin-releasing hormone (TRH) in secondary amenorrhoeic women." | 5.07 | Effects of body weight on responses of serum prolactin to metoclopramide and thyrotrophin-releasing hormone in secondary amenorrhoeic women. ( Aono, T; Higuchi, K; Morishita, H; Takemoto, M; Yoshida, J, 1994) |
| "The effect of metoclopramide on gastroesophageal reflux was studied in 30 infants less than 1 year of age." | 5.06 | Randomized, prospective double-blind trial of metoclopramide and placebo for gastroesophageal reflux in infants. ( Calhoun, J; Kauffman, RE; Kuhns, L; Tolia, V, 1989) |
| "To assess the role of spinal dopamine receptors in mediation of hypotension induced by systemic administration of the dopamine D2 receptor agonist, bromocriptine, conscious deoxycorticosterone acetate (DOCA)-salt hypertensive rats were pretreated with either intravenous (i." | 3.70 | Hypotensive action of bromocriptine in the DOCA-salt hypertensive rat: contribution of spinal dopamine receptors. ( Duarte, GP; Lahlou, S, 1998) |
| " In the present study, the role of nausea in TCDD-induced hypophagia was assessed by a battery of behavioral (conditioned taste aversion [CTA], kaolin consumption, protein selection), biochemical (plasma oxytocin), and antiemetic drug intervention (trimethobenzamine, metoclopramide) approaches." | 3.69 | TCDD-induced hypophagia is not explained by nausea. ( Pohjanvirta, R; Tuomisto, J; Unkila, M, 1994) |
| "Using an original high-pressure liquid chromatographic assay, we measured serum levels of metoclopramide and defined a concentration-response relationship for metoclopramide control of cisplatin-induced emesis." | 3.67 | Optimizing metoclopramide control of cisplatin-induced emesis. ( Drayer, DE; Lewin, M; Lonski, L; Meyer, BR; Pasmantier, M; Reidenberg, MM, 1984) |
| "The responses of luteinizing hormone, follicle-stimulating hormone, and prolactin to prolonged administration of the dopamine receptor antagonist metoclopramide (5 mg twice daily) were investigated in six normal women and six women with low-weight amenorrhea (LWA)." | 3.66 | Responses of luteinizing hormone, follicle-stimulating hormone, and prolactin to prolonged administration of the dopamine antagonist in normal women and women with low-weight amenorrhea. ( Larsen, S, 1981) |
| " A set of core outcomes to standardise infant weight and milk volume measurement is also needed, as well as a strong basis for the dose and dosage form used." | 2.66 | Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants. ( Foong, SC; Foong, WC; Ho, JJ; Marasco, LA; Ong, JH; Tan, ML, 2020) |
| " This study examined the effect of chronic administration of haloperidol, clozapine, sulpiride and metoclopramide on stereotypy and locomotor activity elicited by direct injection of dopamine in to the striatum or nucleus accumbens, respectively." | 1.28 | Regional differences in the induction of behavioral supersensitivity by prolonged treatment with atypical neuroleptics. ( Davis, KL; Guerin, JJ; Halperin, R, 1989) |
| "Body weight was taken as a measure for the assessment of growth rate." | 1.27 | Possible role of dopamine in the growth inhibitory effect of pentazocine. ( Dikshit, RK; Doctor, RB; Gandhi, IC; Shah, UH; Vajpeyee, S, 1983) |
| "Metoclopramide has gained acceptance as an effective drug for the control of nausea and vomiting in cancer patients receiving cisplatin chemotherapy." | 1.27 | Lack of effect of metoclopramide on cisplatin-induced nephrotoxicity in rats. ( Buyan, RD; Perkins, WE; Schroeder, RL, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 18 (54.55) | 18.7374 |
| 1990's | 11 (33.33) | 18.2507 |
| 2000's | 2 (6.06) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (6.06) | 2.80 |
| Authors | Studies |
|---|---|
| Foong, SC | 1 |
| Tan, ML | 1 |
| Foong, WC | 1 |
| Marasco, LA | 1 |
| Ho, JJ | 1 |
| Ong, JH | 1 |
| Mathews, AT | 1 |
| Banks, CM | 1 |
| Trott, JF | 1 |
| Sainz, RD | 1 |
| Farmer, C | 1 |
| Pendergast, II | 1 |
| Hovey, RC | 1 |
| Burger, DM | 1 |
| Wiestner, T | 1 |
| Hubler, M | 1 |
| Binder, H | 1 |
| Keiser, M | 1 |
| Arnold, S | 1 |
| Malcolm, WF | 1 |
| Gantz, M | 1 |
| Martin, RJ | 1 |
| Goldstein, RF | 1 |
| Goldberg, RN | 1 |
| Cotten, CM | 1 |
| Hagen, C | 1 |
| Djursing, H | 1 |
| Petersen, K | 1 |
| Carstensen, L | 1 |
| Gandhi, IC | 1 |
| Vajpeyee, S | 1 |
| Shah, UH | 1 |
| Dikshit, RK | 1 |
| Doctor, RB | 1 |
| Meyer, BR | 1 |
| Lewin, M | 1 |
| Drayer, DE | 1 |
| Pasmantier, M | 1 |
| Lonski, L | 1 |
| Reidenberg, MM | 1 |
| Habbick, BF | 1 |
| Gerrard, JW | 1 |
| Larsen, S | 1 |
| Sowers, J | 1 |
| Catania, R | 1 |
| Paris, J | 1 |
| Tuck, M | 1 |
| Aungst, BJ | 1 |
| Fung, HL | 1 |
| Lautin, A | 1 |
| Wazer, D | 1 |
| Stanley, M | 1 |
| Rotorsen, J | 1 |
| Gershon, S | 1 |
| Rose, JB | 1 |
| McCloskey, JJ | 1 |
| Takemoto, M | 1 |
| Morishita, H | 1 |
| Higuchi, K | 1 |
| Yoshida, J | 1 |
| Aono, T | 1 |
| Pohjanvirta, R | 1 |
| Unkila, M | 1 |
| Tuomisto, J | 1 |
| Amiri, Z | 1 |
| Katz, Y | 1 |
| Weizman, A | 1 |
| Bidder, M | 1 |
| Snyder, SH | 1 |
| Gavish, M | 1 |
| Cullen, MH | 1 |
| Chiodera, P | 1 |
| Volpi, R | 1 |
| Marchesi, C | 1 |
| Caffarra, P | 1 |
| De Ferri, A | 1 |
| Capretti, L | 1 |
| Speroni, G | 1 |
| d'Amato, L | 1 |
| Coiro, V | 1 |
| Polati, E | 1 |
| Verlato, G | 1 |
| Finco, G | 1 |
| Mosaner, W | 1 |
| Grosso, S | 1 |
| Gottin, L | 1 |
| Pinaroli, AM | 1 |
| Ischia, S | 1 |
| Hua, J | 1 |
| Olsson, AR | 1 |
| Pero, RW | 2 |
| Hung, CR | 1 |
| Lahlou, S | 1 |
| Duarte, GP | 1 |
| Norbiato, G | 1 |
| Bevilacqua, M | 1 |
| Raggi, U | 1 |
| Micossi, P | 1 |
| Nitti, F | 1 |
| Lanfredini, M | 1 |
| Barbieri, S | 1 |
| Blum, AL | 1 |
| Bucher, P | 1 |
| Lepsien, G | 1 |
| Weber, K | 1 |
| Giger, M | 1 |
| Sonnenberg, A | 1 |
| Güller, R | 1 |
| Salford, LG | 1 |
| Aas, AT | 1 |
| Brun, A | 1 |
| Halperin, R | 1 |
| Guerin, JJ | 1 |
| Davis, KL | 1 |
| Tolia, V | 1 |
| Calhoun, J | 1 |
| Kuhns, L | 1 |
| Kauffman, RE | 1 |
| Harris, RT | 1 |
| Gupta, AP | 1 |
| Gupta, PK | 1 |
| McCallum, RW | 1 |
| Grill, BB | 1 |
| Lange, R | 1 |
| Planky, M | 1 |
| Glass, EE | 1 |
| Greenfeld, DG | 1 |
| Buyan, RD | 1 |
| Schroeder, RL | 1 |
| Perkins, WE | 1 |
| Palmer, HM | 1 |
| Beardwell, CG | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Placebo-Controlled Study of an Herbal Tea to Support Lactation[NCT02190448] | 60 participants (Actual) | Interventional | 2013-03-31 | Completed | |||
| Metoclopramide to Aid Establishment of Breastfeeding After Delivery: a Randomized Controlled Trial[NCT00264719] | 160 participants (Anticipated) | Interventional | 2006-01-31 | Completed | |||
| Assessing the Feasibility of Testing Domperidone's Effect on Breastfeeding in Women With Insufficient Breast Milk: An RCT Pilot Study[NCT00284024] | Phase 2 | 45 participants (Anticipated) | Interventional | 2006-09-30 | Terminated (stopped due to Unable to recruit participants) | ||
| Efficacy of Herbal Galactogogues on Weight Gain of the Newborns Within the First Month of Life in Breastfeeding Mothers[NCT02740751] | 90 participants (Anticipated) | Interventional | 2016-04-30 | Recruiting | |||
| Metoclopramide to Improve Lactogenesis II in Diabetic Women: a Randomized Controlled Trial[NCT00477776] | Phase 3 | 160 participants (Anticipated) | Interventional | 2006-04-30 | Completed | ||
| Effect of Fenugreek on Milk Production[NCT00851591] | 3 participants (Actual) | Interventional | 2008-09-30 | Terminated (stopped due to Low enrollment; investigator chose not to continue study) | |||
| Efficacy of Herbal Galactogogues: a Double-blinded, Placebo-controlled Randomized Trial.[NCT02233439] | 210 participants (Anticipated) | Interventional | 2014-09-30 | Not yet recruiting | |||
| Effect of Banana Blossom on Breast Milk Volume in Mothers of Preterm Newborns, a Randomized, Double Blinded, Placebo-controlled Trial[NCT05465460] | Phase 4 | 80 participants (Anticipated) | Interventional | 2022-07-09 | Not yet recruiting | ||
| Effects of Non-nutritive Sucking on Gastroesophageal Reflux, Apneas and Bradycardias in Symptomatic Preterm Infants.[NCT02023216] | 30 participants (Actual) | Observational | 2013-05-31 | Completed | |||
| Generic Database: A Survey of Morbidity and Mortality in Very Low Birth Weight Infants[NCT00063063] | 80,000 participants (Anticipated) | Observational | 1987-01-31 | Recruiting | |||
| Effect of Different Modalities of Enteral Tube Feeding (ETF) on Gastroesophageal Reflux (GER) in Symptomatic Preterm Infants[NCT02837627] | 31 participants (Actual) | Observational | 2016-01-01 | Completed | |||
| Follow-up Visit of High Risk Infants[NCT00009633] | 68,000 participants (Anticipated) | Observational | 1993-01-31 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for metoclopramide and Body Weight
| Article | Year |
|---|---|
Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants.
Topics: Administration, Oral; Body Weight; Breast Feeding; Domperidone; Female; Galactogogues; Humans; Infan | 2020 |
Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants.
Topics: Administration, Oral; Body Weight; Breast Feeding; Domperidone; Female; Galactogogues; Humans; Infan | 2020 |
Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants.
Topics: Administration, Oral; Body Weight; Breast Feeding; Domperidone; Female; Galactogogues; Humans; Infan | 2020 |
Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants.
Topics: Administration, Oral; Body Weight; Breast Feeding; Domperidone; Female; Galactogogues; Humans; Infan | 2020 |
Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants.
Topics: Administration, Oral; Body Weight; Breast Feeding; Domperidone; Female; Galactogogues; Humans; Infan | 2020 |
Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants.
Topics: Administration, Oral; Body Weight; Breast Feeding; Domperidone; Female; Galactogogues; Humans; Infan | 2020 |
Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants.
Topics: Administration, Oral; Body Weight; Breast Feeding; Domperidone; Female; Galactogogues; Humans; Infan | 2020 |
Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants.
Topics: Administration, Oral; Body Weight; Breast Feeding; Domperidone; Female; Galactogogues; Humans; Infan | 2020 |
Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants.
Topics: Administration, Oral; Body Weight; Breast Feeding; Domperidone; Female; Galactogogues; Humans; Infan | 2020 |
Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants.
Topics: Administration, Oral; Body Weight; Breast Feeding; Domperidone; Female; Galactogogues; Humans; Infan | 2020 |
Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants.
Topics: Administration, Oral; Body Weight; Breast Feeding; Domperidone; Female; Galactogogues; Humans; Infan | 2020 |
Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants.
Topics: Administration, Oral; Body Weight; Breast Feeding; Domperidone; Female; Galactogogues; Humans; Infan | 2020 |
Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants.
Topics: Administration, Oral; Body Weight; Breast Feeding; Domperidone; Female; Galactogogues; Humans; Infan | 2020 |
Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants.
Topics: Administration, Oral; Body Weight; Breast Feeding; Domperidone; Female; Galactogogues; Humans; Infan | 2020 |
Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants.
Topics: Administration, Oral; Body Weight; Breast Feeding; Domperidone; Female; Galactogogues; Humans; Infan | 2020 |
Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants.
Topics: Administration, Oral; Body Weight; Breast Feeding; Domperidone; Female; Galactogogues; Humans; Infan | 2020 |
Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants.
Topics: Administration, Oral; Body Weight; Breast Feeding; Domperidone; Female; Galactogogues; Humans; Infan | 2020 |
Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants.
Topics: Administration, Oral; Body Weight; Breast Feeding; Domperidone; Female; Galactogogues; Humans; Infan | 2020 |
Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants.
Topics: Administration, Oral; Body Weight; Breast Feeding; Domperidone; Female; Galactogogues; Humans; Infan | 2020 |
Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants.
Topics: Administration, Oral; Body Weight; Breast Feeding; Domperidone; Female; Galactogogues; Humans; Infan | 2020 |
Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants.
Topics: Administration, Oral; Body Weight; Breast Feeding; Domperidone; Female; Galactogogues; Humans; Infan | 2020 |
Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants.
Topics: Administration, Oral; Body Weight; Breast Feeding; Domperidone; Female; Galactogogues; Humans; Infan | 2020 |
Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants.
Topics: Administration, Oral; Body Weight; Breast Feeding; Domperidone; Female; Galactogogues; Humans; Infan | 2020 |
Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants.
Topics: Administration, Oral; Body Weight; Breast Feeding; Domperidone; Female; Galactogogues; Humans; Infan | 2020 |
Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants.
Topics: Administration, Oral; Body Weight; Breast Feeding; Domperidone; Female; Galactogogues; Humans; Infan | 2020 |
Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants.
Topics: Administration, Oral; Body Weight; Breast Feeding; Domperidone; Female; Galactogogues; Humans; Infan | 2020 |
Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants.
Topics: Administration, Oral; Body Weight; Breast Feeding; Domperidone; Female; Galactogogues; Humans; Infan | 2020 |
Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants.
Topics: Administration, Oral; Body Weight; Breast Feeding; Domperidone; Female; Galactogogues; Humans; Infan | 2020 |
Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants.
Topics: Administration, Oral; Body Weight; Breast Feeding; Domperidone; Female; Galactogogues; Humans; Infan | 2020 |
Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants.
Topics: Administration, Oral; Body Weight; Breast Feeding; Domperidone; Female; Galactogogues; Humans; Infan | 2020 |
Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants.
Topics: Administration, Oral; Body Weight; Breast Feeding; Domperidone; Female; Galactogogues; Humans; Infan | 2020 |
Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants.
Topics: Administration, Oral; Body Weight; Breast Feeding; Domperidone; Female; Galactogogues; Humans; Infan | 2020 |
Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants.
Topics: Administration, Oral; Body Weight; Breast Feeding; Domperidone; Female; Galactogogues; Humans; Infan | 2020 |
Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants.
Topics: Administration, Oral; Body Weight; Breast Feeding; Domperidone; Female; Galactogogues; Humans; Infan | 2020 |
Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants.
Topics: Administration, Oral; Body Weight; Breast Feeding; Domperidone; Female; Galactogogues; Humans; Infan | 2020 |
Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants.
Topics: Administration, Oral; Body Weight; Breast Feeding; Domperidone; Female; Galactogogues; Humans; Infan | 2020 |
Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants.
Topics: Administration, Oral; Body Weight; Breast Feeding; Domperidone; Female; Galactogogues; Humans; Infan | 2020 |
Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants.
Topics: Administration, Oral; Body Weight; Breast Feeding; Domperidone; Female; Galactogogues; Humans; Infan | 2020 |
Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants.
Topics: Administration, Oral; Body Weight; Breast Feeding; Domperidone; Female; Galactogogues; Humans; Infan | 2020 |
Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants.
Topics: Administration, Oral; Body Weight; Breast Feeding; Domperidone; Female; Galactogogues; Humans; Infan | 2020 |
Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants.
Topics: Administration, Oral; Body Weight; Breast Feeding; Domperidone; Female; Galactogogues; Humans; Infan | 2020 |
Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants.
Topics: Administration, Oral; Body Weight; Breast Feeding; Domperidone; Female; Galactogogues; Humans; Infan | 2020 |
Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants.
Topics: Administration, Oral; Body Weight; Breast Feeding; Domperidone; Female; Galactogogues; Humans; Infan | 2020 |
Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants.
Topics: Administration, Oral; Body Weight; Breast Feeding; Domperidone; Female; Galactogogues; Humans; Infan | 2020 |
Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants.
Topics: Administration, Oral; Body Weight; Breast Feeding; Domperidone; Female; Galactogogues; Humans; Infan | 2020 |
Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants.
Topics: Administration, Oral; Body Weight; Breast Feeding; Domperidone; Female; Galactogogues; Humans; Infan | 2020 |
Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants.
Topics: Administration, Oral; Body Weight; Breast Feeding; Domperidone; Female; Galactogogues; Humans; Infan | 2020 |
Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants.
Topics: Administration, Oral; Body Weight; Breast Feeding; Domperidone; Female; Galactogogues; Humans; Infan | 2020 |
Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants.
Topics: Administration, Oral; Body Weight; Breast Feeding; Domperidone; Female; Galactogogues; Humans; Infan | 2020 |
Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants.
Topics: Administration, Oral; Body Weight; Breast Feeding; Domperidone; Female; Galactogogues; Humans; Infan | 2020 |
Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants.
Topics: Administration, Oral; Body Weight; Breast Feeding; Domperidone; Female; Galactogogues; Humans; Infan | 2020 |
Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants.
Topics: Administration, Oral; Body Weight; Breast Feeding; Domperidone; Female; Galactogogues; Humans; Infan | 2020 |
Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants.
Topics: Administration, Oral; Body Weight; Breast Feeding; Domperidone; Female; Galactogogues; Humans; Infan | 2020 |
Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants.
Topics: Administration, Oral; Body Weight; Breast Feeding; Domperidone; Female; Galactogogues; Humans; Infan | 2020 |
Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants.
Topics: Administration, Oral; Body Weight; Breast Feeding; Domperidone; Female; Galactogogues; Humans; Infan | 2020 |
Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants.
Topics: Administration, Oral; Body Weight; Breast Feeding; Domperidone; Female; Galactogogues; Humans; Infan | 2020 |
Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants.
Topics: Administration, Oral; Body Weight; Breast Feeding; Domperidone; Female; Galactogogues; Humans; Infan | 2020 |
Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants.
Topics: Administration, Oral; Body Weight; Breast Feeding; Domperidone; Female; Galactogogues; Humans; Infan | 2020 |
Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants.
Topics: Administration, Oral; Body Weight; Breast Feeding; Domperidone; Female; Galactogogues; Humans; Infan | 2020 |
Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants.
Topics: Administration, Oral; Body Weight; Breast Feeding; Domperidone; Female; Galactogogues; Humans; Infan | 2020 |
Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants.
Topics: Administration, Oral; Body Weight; Breast Feeding; Domperidone; Female; Galactogogues; Humans; Infan | 2020 |
Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants.
Topics: Administration, Oral; Body Weight; Breast Feeding; Domperidone; Female; Galactogogues; Humans; Infan | 2020 |
Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants.
Topics: Administration, Oral; Body Weight; Breast Feeding; Domperidone; Female; Galactogogues; Humans; Infan | 2020 |
Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants.
Topics: Administration, Oral; Body Weight; Breast Feeding; Domperidone; Female; Galactogogues; Humans; Infan | 2020 |
Eating disorders: diagnosis and management by the internist.
Topics: Adolescent; Adult; Amenorrhea; Anorexia Nervosa; Attitude; Behavior Therapy; Body Weight; Depressive | 1986 |
5 trials available for metoclopramide and Body Weight
| Article | Year |
|---|---|
Rapid intravenous administration of ondansetron or metoclopramide is not associated with cardiovascular compromise in children.
Topics: Adolescent; Age Factors; Antiemetics; Blood Pressure; Body Weight; Child; Child, Preschool; Double-B | 1995 |
Effects of body weight on responses of serum prolactin to metoclopramide and thyrotrophin-releasing hormone in secondary amenorrhoeic women.
Topics: Adult; Amenorrhea; Body Weight; Estradiol; Estrone; Female; Follicle Stimulating Hormone; Humans; Lu | 1994 |
Mitomycin, ifosfamide, and cisplatin in non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Carcinoma, Non-Small-Cell | 1993 |
Ondansetron versus metoclopramide in the treatment of postoperative nausea and vomiting.
Topics: Adolescent; Adult; Age Factors; Aged; Anesthesia Recovery Period; Anesthetics, Intravenous; Antiemet | 1997 |
Randomized, prospective double-blind trial of metoclopramide and placebo for gastroesophageal reflux in infants.
Topics: Body Weight; Clinical Trials as Topic; Double-Blind Method; Gastric Emptying; Gastroesophageal Reflu | 1989 |
26 other studies available for metoclopramide and Body Weight
| Article | Year |
|---|---|
Metoclopramide induces preparturient, low-level hyperprolactinemia to increase milk production in primiparous sows.
Topics: Animal Nutritional Physiological Phenomena; Animals; Animals, Newborn; Body Weight; Dopamine D2 Rece | 2021 |
Effect of anticholinergics (atropine, glycopyrrolate) and prokinetics (metoclopramide, cisapride) on gastric motility in beagles and labrador retrievers.
Topics: Animals; Atropine; Body Weight; Breeding; Cisapride; Dogs; Dose-Response Relationship, Drug; Electro | 2006 |
Use of medications for gastroesophageal reflux at discharge among extremely low birth weight infants.
Topics: Body Weight; Child Development; Cohort Studies; Continuity of Patient Care; Dose-Response Relationsh | 2008 |
Use of medications for gastroesophageal reflux at discharge among extremely low birth weight infants.
Topics: Body Weight; Child Development; Cohort Studies; Continuity of Patient Care; Dose-Response Relationsh | 2008 |
Use of medications for gastroesophageal reflux at discharge among extremely low birth weight infants.
Topics: Body Weight; Child Development; Cohort Studies; Continuity of Patient Care; Dose-Response Relationsh | 2008 |
Use of medications for gastroesophageal reflux at discharge among extremely low birth weight infants.
Topics: Body Weight; Child Development; Cohort Studies; Continuity of Patient Care; Dose-Response Relationsh | 2008 |
Use of medications for gastroesophageal reflux at discharge among extremely low birth weight infants.
Topics: Body Weight; Child Development; Cohort Studies; Continuity of Patient Care; Dose-Response Relationsh | 2008 |
Use of medications for gastroesophageal reflux at discharge among extremely low birth weight infants.
Topics: Body Weight; Child Development; Cohort Studies; Continuity of Patient Care; Dose-Response Relationsh | 2008 |
Use of medications for gastroesophageal reflux at discharge among extremely low birth weight infants.
Topics: Body Weight; Child Development; Cohort Studies; Continuity of Patient Care; Dose-Response Relationsh | 2008 |
Use of medications for gastroesophageal reflux at discharge among extremely low birth weight infants.
Topics: Body Weight; Child Development; Cohort Studies; Continuity of Patient Care; Dose-Response Relationsh | 2008 |
Use of medications for gastroesophageal reflux at discharge among extremely low birth weight infants.
Topics: Body Weight; Child Development; Cohort Studies; Continuity of Patient Care; Dose-Response Relationsh | 2008 |
Use of medications for gastroesophageal reflux at discharge among extremely low birth weight infants.
Topics: Body Weight; Child Development; Cohort Studies; Continuity of Patient Care; Dose-Response Relationsh | 2008 |
Use of medications for gastroesophageal reflux at discharge among extremely low birth weight infants.
Topics: Body Weight; Child Development; Cohort Studies; Continuity of Patient Care; Dose-Response Relationsh | 2008 |
Use of medications for gastroesophageal reflux at discharge among extremely low birth weight infants.
Topics: Body Weight; Child Development; Cohort Studies; Continuity of Patient Care; Dose-Response Relationsh | 2008 |
Use of medications for gastroesophageal reflux at discharge among extremely low birth weight infants.
Topics: Body Weight; Child Development; Cohort Studies; Continuity of Patient Care; Dose-Response Relationsh | 2008 |
Use of medications for gastroesophageal reflux at discharge among extremely low birth weight infants.
Topics: Body Weight; Child Development; Cohort Studies; Continuity of Patient Care; Dose-Response Relationsh | 2008 |
Use of medications for gastroesophageal reflux at discharge among extremely low birth weight infants.
Topics: Body Weight; Child Development; Cohort Studies; Continuity of Patient Care; Dose-Response Relationsh | 2008 |
Use of medications for gastroesophageal reflux at discharge among extremely low birth weight infants.
Topics: Body Weight; Child Development; Cohort Studies; Continuity of Patient Care; Dose-Response Relationsh | 2008 |
Metoclopramide for normoprolactinaemic amenorrhoea.
Topics: Adult; Amenorrhea; Body Weight; Female; Humans; Metoclopramide; Prolactin | 1983 |
Possible role of dopamine in the growth inhibitory effect of pentazocine.
Topics: Animals; Body Weight; Dopamine; Dopamine Antagonists; Drug Synergism; Growth; Levodopa; Metocloprami | 1983 |
Optimizing metoclopramide control of cisplatin-induced emesis.
Topics: Adult; Aged; Body Weight; Chromatography, High Pressure Liquid; Cisplatin; Diarrhea; Drug Administra | 1984 |
Failure to thrive in the contented breast-fed baby.
Topics: Body Height; Body Weight; Breast Feeding; Chlorpromazine; Failure to Thrive; Female; Humans; Infant; | 1984 |
Responses of luteinizing hormone, follicle-stimulating hormone, and prolactin to prolonged administration of the dopamine antagonist in normal women and women with low-weight amenorrhea.
Topics: Adolescent; Adult; Amenorrhea; Body Weight; Child; Female; Follicle Stimulating Hormone; Humans; Lut | 1981 |
Effects of bromocriptine on renin, aldosterone, and prolactin responses to posture and metoclopramide in idiopathic edema: possible therapeutic approach.
Topics: Adult; Aldosterone; Blood Pressure; Body Weight; Edema; Female; Humans; Isometric Contraction; Kinet | 1982 |
Intestinal lead absorption in rats: effects of circadian rhythm, food, undernourishment, and drugs which alter gastric emptying and GI motility.
Topics: Animals; Body Weight; Circadian Rhythm; Diet; Fasting; Gastric Emptying; Gastrointestinal Motility; | 1981 |
Chronic treatment with metoclopramide induces behavioral supersensitivity to apomorphine and enhances specific binding of 3H-spiroperidol to rat striata.
Topics: Animals; Apomorphine; Behavior, Animal; Binding, Competitive; Body Weight; Butyrophenones; Corpus St | 1980 |
TCDD-induced hypophagia is not explained by nausea.
Topics: Animals; Antiemetics; Benzamides; Body Weight; Eating; Energy Metabolism; Female; Kaolin; Male; Meto | 1994 |
Adrenal mitochondrial benzodiazepine receptors are sensitive to agents active at the dopamine receptor.
Topics: Adrenal Glands; Animals; Body Weight; Bromocriptine; Isoquinolines; Kidney; Male; Metoclopramide; Mi | 1993 |
Reduction in the arginine vasopressin responses to metoclopramide and insulin-induced hypoglycemia in normal weight bulimic women.
Topics: Adult; Arginine Vasopressin; Blood Glucose; Body Weight; Bulimia; Female; Humans; Insulin; Metoclopr | 1993 |
Neutral metoclopramide sensitizes cytotoxicity induced by ionizing radiation in SCID mice xenografted with a human brain astrocytoma.
Topics: Animals; Astrocytoma; Blood-Brain Barrier; Body Weight; Brain; Chromatography, High Pressure Liquid; | 1997 |
Low susceptibility of stress ulcer in diabetic rats: role of cholinergic gastric motility.
Topics: Animals; Antiemetics; Antimetabolites; Atropine; Bethanechol; Blood Glucose; Body Weight; Cholinergi | 1998 |
Hypotensive action of bromocriptine in the DOCA-salt hypertensive rat: contribution of spinal dopamine receptors.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Body Weight; Bromocriptine; Desoxycorticosterone; | 1998 |
Effect of metoclopramide, a dopaminergic inhibitor, on renin and aldosterone in idiopathic edema: possible therapeutic approach with levodopa and carbidopa.
Topics: Adult; Aldosterone; Body Weight; Carbidopa; Edema; Female; Humans; Hydrazines; Levodopa; Metoclopram | 1979 |
[Treatment of reflux disease (author's transl)].
Topics: Alginates; Antacids; Body Weight; Cimetidine; Esophagitis; Gastroesophageal Reflux; Humans; Metoclop | 1978 |
[Gastro-esophageal Reflux (present concept of pathogenesis and therapy (author's transl)].
Topics: Antacids; Body Weight; Gastroesophageal Reflux; Metoclopramide; Posture; Pressure | 1976 |
Metoclopramide as a sensitizer of 1,3-bis(2-chloroethyl)-1-nitrosourea treatment of brain tumors in the rat.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Brain Neoplasms; Carmustine; F | 1992 |
Regional differences in the induction of behavioral supersensitivity by prolonged treatment with atypical neuroleptics.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Body Weight; Clozapine; Corpus Striatum; Dopamine; | 1989 |
Metoclopramide as a lactogogue.
Topics: Adult; Body Weight; Breast Feeding; Drug Evaluation; Female; Humans; Lactation Disorders; Metoclopra | 1985 |
Definition of a gastric emptying abnormality in patients with anorexia nervosa.
Topics: Adolescent; Adult; Anorexia Nervosa; Body Weight; Child; Demography; Female; Gastric Emptying; Human | 1985 |
Lack of effect of metoclopramide on cisplatin-induced nephrotoxicity in rats.
Topics: Animals; Body Weight; Cisplatin; Female; Kidney; Kidney Diseases; Metoclopramide; Rats; Rats, Inbred | 1985 |
Hyperthyroidism presenting with acute abdominal symptoms.
Topics: Abdomen, Acute; Adult; Antacids; Body Weight; Carbimazole; Colic; Diarrhea; Female; Goiter; Hemateme | 1974 |